Alberta Investment Management Corp Has $6.08 Million Position in Zai Lab Limited (NASDAQ:ZLAB)

Alberta Investment Management Corp boosted its position in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 42.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 232,293 shares of the company's stock after buying an additional 69,740 shares during the quarter. Alberta Investment Management Corp owned approximately 0.21% of Zai Lab worth $6,084,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZLAB. Y Intercept Hong Kong Ltd acquired a new stake in Zai Lab in the 3rd quarter valued at approximately $225,000. China Universal Asset Management Co. Ltd. raised its position in Zai Lab by 58.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,559 shares of the company's stock valued at $231,000 after buying an additional 3,514 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Zai Lab by 4,851.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company's stock valued at $231,000 after buying an additional 9,364 shares during the last quarter. RBF Capital LLC acquired a new stake in Zai Lab in the 3rd quarter valued at approximately $241,000. Finally, Point72 Asset Management L.P. acquired a new stake in Zai Lab in the 3rd quarter valued at approximately $325,000. Institutional investors and hedge funds own 41.65% of the company's stock.

Zai Lab Price Performance

ZLAB stock traded up $2.79 during mid-day trading on Friday, reaching $33.78. The company had a trading volume of 2,093,498 shares, compared to its average volume of 677,581. The stock has a 50 day simple moving average of $26.90 and a two-hundred day simple moving average of $25.22. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of -12.19 and a beta of 1.02. Zai Lab Limited has a 52 week low of $13.48 and a 52 week high of $36.60.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the transaction, the insider now directly owns 33,834 shares in the company, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 13.88% of the company's stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald upgraded Zai Lab to a "strong-buy" rating in a research note on Wednesday, February 5th.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.